questionsmedicales.fr
Cellules
Neurones
Neurofibrilles
Enchevêtrements neurofibrillaires
Enchevêtrements neurofibrillaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Enchevêtrements neurofibrillaires : Questions médicales les plus fréquentes",
"headline": "Enchevêtrements neurofibrillaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Enchevêtrements neurofibrillaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-21",
"dateModified": "2025-04-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Enchevêtrements neurofibrillaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Neurofibrilles",
"url": "https://questionsmedicales.fr/mesh/D009454",
"about": {
"@type": "MedicalCondition",
"name": "Neurofibrilles",
"code": {
"@type": "MedicalCode",
"code": "D009454",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.671.573"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Enchevêtrements neurofibrillaires",
"alternateName": "Neurofibrillary Tangles",
"code": {
"@type": "MedicalCode",
"code": "D016874",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Bradley T Hyman",
"url": "https://questionsmedicales.fr/author/Bradley%20T%20Hyman",
"affiliation": {
"@type": "Organization",
"name": "Massachusetts General Hospital, Neurology Dept. Boston, MA 02114."
}
},
{
"@type": "Person",
"name": "Thomas G Beach",
"url": "https://questionsmedicales.fr/author/Thomas%20G%20Beach",
"affiliation": {
"@type": "Organization",
"name": "Banner Sun Health Research Institute, Sun City, Ariz."
}
},
{
"@type": "Person",
"name": "Geidy E Serrano",
"url": "https://questionsmedicales.fr/author/Geidy%20E%20Serrano",
"affiliation": {
"@type": "Organization",
"name": "Banner Sun Health Research Institute, Sun City, Ariz."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Henrik Zetterberg",
"url": "https://questionsmedicales.fr/author/Henrik%20Zetterberg",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Angiogenic Effect of a Nanoniosomal Deferoxamine-Loaded Poly(vinyl alcohol)-Egg White Film as a Promising Wound Dressing.",
"datePublished": "2022-07-05",
"url": "https://questionsmedicales.fr/article/35786844",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsbiomaterials.2c00046"
}
},
{
"@type": "ScholarlyArticle",
"name": "Deferoxamine Promotes Peripheral Nerve Regeneration by Enhancing Schwann Cell Function and Promoting Axon Regeneration of Dorsal Root Ganglion.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37286159",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neuroscience.2023.05.029"
}
},
{
"@type": "ScholarlyArticle",
"name": "High ferritin is associated with liver and bone marrow iron accumulation: Effects of 1-year deferoxamine treatment in hemodialysis-associated iron overload.",
"datePublished": "2024-08-09",
"url": "https://questionsmedicales.fr/article/39121099",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0306255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metabolites from scutellarin alleviating deferoxamine-induced hypoxia injury in BV2 cells cultured on microfluidic chip combined with a mass spectrometer.",
"datePublished": "2023-03-23",
"url": "https://questionsmedicales.fr/article/36989966",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.talanta.2023.124478"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of Renal Cell Carcinoma Cell Response to the Enhancement of 5-aminolevulinic Acid-mediated Protoporphyrin IX Fluorescence by Iron Chelator Deferoxamine",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35857390",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/php.13678"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Neurones",
"item": "https://questionsmedicales.fr/mesh/D009474"
},
{
"@type": "ListItem",
"position": 4,
"name": "Neurofibrilles",
"item": "https://questionsmedicales.fr/mesh/D009454"
},
{
"@type": "ListItem",
"position": 5,
"name": "Enchevêtrements neurofibrillaires",
"item": "https://questionsmedicales.fr/mesh/D016874"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Enchevêtrements neurofibrillaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Enchevêtrements neurofibrillaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Enchevêtrements neurofibrillaires",
"description": "Comment diagnostique-t-on les enchevêtrements neurofibrillaires ?\nQuels tests d'imagerie sont utilisés ?\nLes biomarqueurs sont-ils utiles ?\nPeut-on diagnostiquer précocement ?\nQuel rôle joue l'autopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D016874?mesh_terms=Deferoxamine&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Enchevêtrements neurofibrillaires",
"description": "Quels sont les symptômes associés aux enchevêtrements ?\nLes enchevêtrements causent-ils des changements de comportement ?\nY a-t-il des symptômes physiques ?\nLes symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D016874?mesh_terms=Deferoxamine&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Enchevêtrements neurofibrillaires",
"description": "Peut-on prévenir les enchevêtrements neurofibrillaires ?\nL'exercice physique est-il bénéfique ?\nLe contrôle du stress aide-t-il ?\nUne alimentation spécifique peut-elle aider ?\nLes activités sociales sont-elles importantes ?",
"url": "https://questionsmedicales.fr/mesh/D016874?mesh_terms=Deferoxamine&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Enchevêtrements neurofibrillaires",
"description": "Quels traitements existent pour les enchevêtrements ?\nLes thérapies cognitives sont-elles efficaces ?\nY a-t-il des traitements expérimentaux ?\nLes médicaments antidépressifs sont-ils utiles ?\nLa nutrition joue-t-elle un rôle dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D016874?mesh_terms=Deferoxamine&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Enchevêtrements neurofibrillaires",
"description": "Quelles complications peuvent survenir ?\nLes enchevêtrements augmentent-ils le risque de démence ?\nY a-t-il des complications physiques ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D016874?mesh_terms=Deferoxamine&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Enchevêtrements neurofibrillaires",
"description": "Quels sont les principaux facteurs de risque ?\nLe sexe influence-t-il le risque ?\nLes maladies cardiovasculaires sont-elles un facteur ?\nLe niveau d'éducation joue-t-il un rôle ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D016874?mesh_terms=Deferoxamine&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on les enchevêtrements neurofibrillaires ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen histopathologique du tissu cérébral post-mortem."
}
},
{
"@type": "Question",
"name": "Quels tests d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et la TEP peuvent aider à détecter des anomalies cérébrales associées."
}
},
{
"@type": "Question",
"name": "Les biomarqueurs sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biomarqueurs dans le liquide céphalorachidien peuvent indiquer la présence d'enchevêtrements."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer précocement ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic précoce est difficile, mais des tests cognitifs peuvent aider."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'autopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'autopsie permet de confirmer la présence d'enchevêtrements neurofibrillaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes associés aux enchevêtrements ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la perte de mémoire, la confusion et des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Les enchevêtrements causent-ils des changements de comportement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner des changements d'humeur et des comportements anormaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont principalement cognitifs, mais des troubles moteurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge du patient."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes liés aux enchevêtrements neurofibrillaires sont généralement irréversibles."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les enchevêtrements neurofibrillaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode prouvée pour prévenir leur formation, mais un mode de vie sain aide."
}
},
{
"@type": "Question",
"name": "L'exercice physique est-il bénéfique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier est associé à une meilleure santé cognitive et peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Le contrôle du stress aide-t-il ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Gérer le stress peut contribuer à la santé cérébrale, bien que son impact sur les enchevêtrements soit incertain."
}
},
{
"@type": "Question",
"name": "Une alimentation spécifique peut-elle aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants et en oméga-3 est bénéfique pour la santé cérébrale."
}
},
{
"@type": "Question",
"name": "Les activités sociales sont-elles importantes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'engagement social peut aider à maintenir la santé cognitive et réduire les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les enchevêtrements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique, mais des médicaments peuvent soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Les thérapies cognitives sont-elles efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies cognitives peuvent aider à gérer les symptômes, mais ne stoppent pas la progression."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur des traitements visant à réduire les enchevêtrements tau."
}
},
{
"@type": "Question",
"name": "Les médicaments antidépressifs sont-ils utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent aider à traiter les symptômes dépressifs associés aux troubles cognitifs."
}
},
{
"@type": "Question",
"name": "La nutrition joue-t-elle un rôle dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut soutenir la santé cérébrale, mais ne traite pas directement les enchevêtrements."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent une détérioration cognitive sévère et des troubles de la mémoire."
}
},
{
"@type": "Question",
"name": "Les enchevêtrements augmentent-ils le risque de démence ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur présence est fortement associée à un risque accru de démence, notamment Alzheimer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications physiques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications physiques peuvent survenir, comme des chutes dues à des troubles moteurs."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent gravement affecter la qualité de vie des patients et de leurs familles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les complications liées aux enchevêtrements neurofibrillaires sont généralement irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les antécédents familiaux et certaines conditions médicales augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes semblent avoir un risque plus élevé de développer des enchevêtrements."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles un facteur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies cardiovasculaires peuvent augmenter le risque de développer des enchevêtrements."
}
},
{
"@type": "Question",
"name": "Le niveau d'éducation joue-t-il un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un niveau d'éducation plus élevé est associé à un risque réduit de démence et d'enchevêtrements."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie actif et une alimentation saine peuvent réduire le risque d'enchevêtrements."
}
}
]
}
]
}
Owing to the noticeable increase in the number of patients with impaired wound healing capabilities, developing bioactive wound dressings with supportive physicomechanical and biological properties fo...
Deferoxamine (DFO) is a potent iron chelator for clinical treatment of various diseases. Recent studies have also shown its potential to promote vascular regeneration during peripheral nerve regenerat...
Iron (Fe) supplementation is a critical component of anemia therapy for patients with chronic kidney disease (CKD). However, serum Fe, ferritin, and transferrin saturation, used to guide Fe replacemen...
We prospectively enrolled 28 patients with CKD on hemodialysis with high serum ferritin (> 1000 ng/ml) and tested the effects of 1-year deferoxamine treatment, accompanied by withdrawal of Fe administ...
MRI parameters showed that none of the patients had heart iron overload, but they all presented iron overload in the liver and bone marrow, which was confirmed by bone histology. After therapy, ferrit...
Our data suggest that treatment with deferoxamine was safe and could improve Fe accumulation, as measured by MRI and histomorphometry. Whether MRI is considered a standard tool for investigating bone ...
The changes of metabolites of tricarboxylic acid (TCA) cycle in cells under hypoxia play a key role in drug screening. In order to dynamically monitor the drug metabolism changes of Scutellarin in the...
As a tumor photodiagnostic agent, 5-aminolevulinic acid (ALA) is metabolized in the heme biosynthesis pathway to produce protoporphyrin IX (PpIX) with fluorescence. ALA-PpIX fluorescence was evaluated...
Children with sickle cell disease (SCD) who are chronically transfused often, require iron chelation therapy. There are limited data that allow for comparison of the efficacy and safety of the iron ch...
This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younge...
Overall, 142 patients were evaluated; mean ages were 10.5 and 11.7 years in the deferiprone and deferoxamine groups, respectively. At 12 months: mean change from baseline in liver iron concentration w...
This post hoc analysis of pediatric patients from FIRST corroborated previous findings in adults that deferiprone is comparable to deferoxamine in reducing iron overload. No new safety concerns were o...
Intracerebral hemorrhage (ICH) is a subtype of stroke that is characterized by high morbidity and mortality, for which clinical outcome remains poor. An extensive literature indicates that the release...
Background Radiation-induced fibrosis (RIF) is a debilitating sequelae of radiation therapy that has been shown to improve with topical treatment with the iron chelator deferoxamine (DFO). We investig...
Deferoxamine (DFO) is a water-soluble iron chelator used pharmacologically for the management of patients with transfusional iron overload. However, DFO is not cell-permeable and has a short plasma ha...
Iron is widely linked with the onset and development of Parkinson's disease (PD). Accumulation of iron induces free radical generation and promotes α-synuclein aggregation, oxidative stress, and autop...